Dong-A ST Co., Ltd. (KRX:170900)

South Korea flag South Korea · Delayed Price · Currency is KRW
44,650
-700 (-1.54%)
Apr 29, 2026, 1:30 PM KST
3.04%
Market Cap 435.92B
Revenue (ttm) 808.78B
Net Income (ttm) -28.59B
Shares Out 9.61M
EPS (ttm) -2,970.54
PE Ratio n/a
Forward PE 12.72
Dividend 666.67 (1.46%)
Ex-Dividend Date Mar 10, 2026
Volume 10,987
Average Volume 13,873
Open 45,300
Previous Close 45,350
Day's Range 44,650 - 45,300
52-Week Range 40,476 - 56,381
Beta 0.50
RSI 50.26
Earnings Date Apr 27, 2026

About Dong-A ST

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and anovulation; Growtropin II Inj./AQ /cartridge to treat growth failure d... [Read more]

Sector Healthcare
Founded 1932
Employees 1,679
Stock Exchange Korea Stock Exchange
Ticker Symbol 170900
Full Company Profile

Financial Performance

In 2025, Dong-A ST's revenue was 808.78 billion, an increase of 15.89% compared to the previous year's 697.87 billion. Losses were -28.59 billion, 2237.8% more than in 2024.

Financial Statements

News

Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA

– Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations SEOUL, South Korea — Dong-A ST (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, IMULD...

1 year ago - Financial Post

US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®

Dong-A ST’s biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration SEOUL, South Korea — Dong-A ST (President/CEO Jae-Hun Jung...

1 year ago - Financial Post

US FDA Approves Dong-A ST's IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®

Dong-A ST's biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration Dong-A ST (President/CEO Jae-Hun Jung, KRX: 170900) announ...

1 year ago - Benzinga